D. Ross Camidge, MD, PhD, professor, medicine-medical oncology; director, Thoracic Oncology Clinical Program, Clinical Research Program, University of Colorado Cancer Center outlines the key role of biomarker testing in non-small cell lung cancer (NSCLC), focusing on ALK mutations and the importance of comprehensive testing. He highlights challenges in interpretation and treatment resistance, calling for precision medicine and the potential benefits of longitudinal biomarker testing.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045